YOLT-203 not checked
FollowEvery change as it happens, and a Monday email
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “YOLT-203 is an investigational gene editing therapy being evaluated for the treatment of Primary Hyperoxaluria Type 1 (PH1). It is administered by intravenous infusion over 1 hour.”In the company’s words, NCT07587021 on ClinicalTrials.gov
- Tested for
- Primary Hyperoxaluria Type 1, PH1
- Main trialPhase 2
- “This study will be conducted to evaluate the efficacy and safety of YOLT-203 in children and adults with Primary Hyperoxaluria Type 1. After the initial randomized, 6-month double-blind, placebo-controlled period, participants who were initially assigned to placebo will receive a single-dose of YOLT-203 treatment whereas participants in the YOLT-203 group will receive a single-dose of placebo infusion. For patients interested in additional information on how to participate, please follow this link: https://mytomorro.ws/ph1trial.”In the company’s words, NCT07587021 on ClinicalTrials.gov
- Other names
- Investigational Gene Editing Therapy
Other drugs for Primary Hyperoxaluria Type 1
- NedosiranNovo Nordisk · Phase 3
- StiripentolBiocodex · Phase 3
- ABO-101Arbor Biotechnologies · Phase 1/2
Coming up1
- Aug 2027Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Recruiting | Aug 2027 | Study of YOLT-203 in Children and Adults With Primary Hyperoxaluria Type 1 (PH1) |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026